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Atherosclerosis and apolipoprotein E 𝜀𝜀4 (APOE4) genotype are risk factors for Alzheimer’s disease (AD) and cardiovascular disease
(CVD). Sex diﬀerences exist in prevalence and manifestation of both diseases. We investigated sex diﬀerences respective to aging,
focusing on cognitive parameters in apoE4 and apoE knockout (ko) mouse models of AD and CVD. Presynaptic density and
neurogenesis were investigated immunohistochemically in male and female apoE4, apoE ko, and wild-type mice. Middle-aged
female apoE4 mice showed decreased presynaptic density in the inner molecular layer of the dentate gyrus of the hippocampus.
Middle-aged female apoE ko mice showed a trend towards increased neurogenesis in the hippocampus compared with wild-type
mice. No diﬀerences in these parameters could be observed inmiddle-agedmalemice. Speci�c harmful interactions between apoE4
and estrogen could be responsible for decreased presynaptic density in female apoE4 mice. e trend of increased neurogenesis
found in female apoE ko mice supports previous studies suggesting that temporarily increased amount of synaptic contacts and/or
neurogenesis is a compensatory mechanism for synaptic failure. To our knowledge, no other studies investigating presynaptic
density in aging female apoE4 or apoE ko mice are available. Sex-speci�c diﬀerences between APOE genotypes could account
for some sex diﬀerences in AD and CVD.
1. Introduction
Western society is currently faced with an increasing inci-
dence of vascular diseases such as hypercholesterolemia
and atherosclerosis, mainly as a consequence of unhealthy
lifestyle habits, an increase in obesity, and an aging pop-
ulation. Vascular diseases and obesity are risk factors for
disorders that aﬀect cognitive function such as diabetesmelli-
tus, stroke, vascular dementia, and Alzheimer’s disease (AD)
[1, 2]. Sex diﬀerences exist in both AD and cardiovascular
disease (CVD). While women have a higher risk for AD,
men are generally more aﬀected by CVD [3]. For example,
men are more prone to develop high serum cholesterol levels
at a younger age than (premenopausal) women [4, 5]. Most
of these sex diﬀerences disappear, however, when women
reach menopause, when they equal and even surpass men
in the prevalence of CVD [3, 6]. However, diﬀerences in the
manifestation of CVD remain. For example, while men have
thicker atherosclerotic plaques in the large coronary arteries,
women tend to havemore diﬀuse plaques that also impair the
smaller microvasculature [4, 5, 7].
One factor in�uencing the prevalence of both vascular
and Alzheimer’s disease is the apolipoprotein E (APOE)
genotype. e APOE genotype is a genetic risk factor for
sporadic or late-onset AD. e risk for AD is increased
in carriers of the 𝜀𝜀4 allele [8, 9], and the age of onset is
decreased [8, 10] compared with 𝜀𝜀2 and 𝜀𝜀3 allele carriers.
Furthermore, in the nondemented elderly population and in
healthy middle-aged people, the 𝜀𝜀4 allele is also associated
with memory decline [11–14]. e APOE gene encodes for
the apolipoprotein E protein (apoE), which has several roles
in the body and in the brain.ese include anti-in�ammatory
and antioxidant eﬀects [15–17] and cholesterol transport
[18]. e apoE4 isoform is a poorer functioning cholesterol
transporter, which contributes to hypercholesterolemia [19,
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20], which in turn causes atherosclerosis. In addition, it has
been shown in the brain that less apoE3 than apoE4 is needed
for similar sized lipid particles, suggesting an impaired or less
eﬀective delivery of cholesterol to neurons [21]. Furthermore,
apoE is involved in the clearance of amyloid-beta (A𝛽𝛽) from
the brain across the blood brain barrier [22]. Increased
levels of A𝛽𝛽 in the brain lead to an increased risk of AD,
and A𝛽𝛽 accumulation in blood vessel walls may lead to
cerebral amyloid angiopathy. Obstruction of blood vessels
by atherosclerosis or cerebral amyloid angiopathy can aﬀect
cognition by causing cerebral hypoperfusion. is reduces
neuronal protein synthesis, which is important for synaptic
plasticity [23]. Furthermore, it has been shown that cerebral
blood �ow (CBF) is reduced in AD patients [24], and CBF
reductions are predictive of conversion toAD in patients with
mild cognitive impairment [25].
As with CVD and AD, the APOE genotype has diﬀer-
ential eﬀects between the sexes. e increased risk for AD
and cognitive de�cits in the nondemented population in 𝜀𝜀4
carriers is higher in women [26–28]. Furthermore, female
apoE4mice show spatialmemory de�cits [29, 30]. Estrogen is
one factor that interacts with apoE, and as such could explain
these eﬀects. For example, hormone replacement therapy
in menopausal women may not be bene�cial for cognition
in carriers of an 𝜀𝜀4 allele [31, 32]. Additionally, whereas
estradiol facilitates neurite outgrowth in the presence of
apoE2 and apoE3, it does not do so in the presence of
apoE4 [33]. In addition, brain apoE levels can be aﬀected by
pharmacological estrogen treatment, and this eﬀect is brain
region-speci�c,most likely due to the diﬀerential distribution
of estrogen receptor subtypes [34].
e aim of the current study was to investigate sex dif-
ferences in apoE, focusing on parameters that are important
for cognitive functioning. erefore, we studied presynaptic
density and neurogenesis inmale and female apoE4 and apoE
knockoutmice, which aremodels of AD and vascular disease.
2. Experimental Procedures
2.1. Animals. Homozygous apoE-de�cient (B6.129P2-
Apoe tm1Unc /J) mice were originally obtained from Jackson
Laboratories (Bar Harbor, ME, USA) and subsequently
bred in the Central Animal Laboratory (CDL; Radboud
University Nijmegen Medical Centre, RUNMC). e
background strain for these apoE knockout (apoE ko) mice
is C57BL6/J. Homozygous human APOE4 knockin mice
were originally obtained from Taconic Transgenic Models
(Hudson, NY, USA) and subsequently bred in the Central
Animal Laboratory (RUNMC). In this strain, the murine
ApoE gene is replaced with the human APOE4 alleles (4/4),
aer which the strain is backcrossed to C57BL6/J mice.
C57BL6/J wild-type (WT) mice were originally obtained
from Harlan Laboratories, Inc. (Horst, e Netherlands) and
subsequently bred in the CDL (RUNMC).
In total, 22malemice and 21 femalemice of the 3 diﬀerent
genotypes (WT, apoE4, and apoE ko) aged 9–15 months
(males: 9–12 months, M: 10.7; females: 12–15 months, M:
13.2) were used in this study. e mice were housed in
standard cages (Makrolon type 3, 42.5 × 26.5 × 15.5 cm, with
maximum 11 animals per cage) at 21∘C on a 12 h light/dark
cycle (lights on at 7 a.m.) andwere fed rodent lab chow.Water
and food were provided ad libitum.ere were no diﬀerences
in brain or body weight between the genotypes in males or
females.
e experiments were performed according to Dutch
federal regulations for animal protection and were approved
by the Veterinary Authority of the Radboud University
NijmegenMedical Centre (permit numbers 11-090 and 2008-
172).
2.2. Tissue Preparation. Mice were anaesthetised with iso�u-
rane (3-3.5% in a mixture of oxygen and N2O (2 : 1))
and transcardially perfused with phosphate buﬀered saline
(0.1M PBS) and with 4% paraformaldehyde. e brains
were removed immediately aer perfusion �xation, post�xed
overnight in 4% paraformaldehyde at 4∘C, and transferred
the next day to 0.1M PBS containing 1% sodium azide.
e brains were placed in 30% sucrose in 0.1M phosphate
buﬀer for 24 hours before cutting 40𝜇𝜇m coronal sections on
a sliding microtome (Microm HM 440, Walldorf, Germany)
equipped with an object table for freeze-sectioning at −60∘C.
Sections were divided into 6 complete series (1 out of every
6 sections) while cutting. e sections were stored in 0.1M
PBS with 1% sodium azide at 4∘C until they were used for
immunohistochemistry.
2.3. Immunohistochemistry. All staining was carried out
according to standard protocols, and all stepswere performed
at room temperature on a shaker table. e staining was
performed in separate sessions; male apoE4, apoE ko, and
WT mice were stained in one group, and female apoE4,
apoE ko, and WT mice were stained in another group.
Before each staining session, a test staining was performed to
determine the optimal antibody concentration. Free-�oating
brain sections were �rst rinsed (rinsing of sections was
always donewith 0.1MPBS) and endogenous peroxidase was
blocked with 0.3% H2O2 in 0.1M PBS. e sections were
rinsed again and preincubated with 0.1M PBS-BT (0.1M
PBS with 1% Bovine Serum Albumin and 0.3% Triton-
X-100). e sections were then incubated overnight with
a primary antibody (monoclonal rabbit anti-synaptophysin
clone EP1098Y, 1:20000 in PBS-BT for males, 1:10000 in
PBS-BT for females, Abcam Inc., Cambridge, UK; goat
anti-Doublecortin (C18): sc-8066, 1:3000 in PBS-BT, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Aer
another rinse, the sections were incubated for 90min with
a secondary antibody (donkey anti-rabbit biotinylated IgG,
1:1500 in PBS-BT, Jackson ImmunoResearch, West Grove,
PA, USA; donkey-anti-goat biotinylated IgG, 1:1500 in PBS-
BT, Jackson ImmunoResearch,West Grove, PA, USA), rinsed
again, and incubated with Vector ABC-Elite (A and B, 1:800
in PBS-BT, Vector Laboratories, Burlingame, CA, USA).
Finally, the sections were rinsed, preincubated with DAB-
Nickel solution, incubated with DAB-Nickel solution with
0.3%H2O2, and rinsed to stop the reaction.e sections were
mounted on gelatin-coated object glasses (0.5% gelatin and
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0.05% chrome aluminium sulphate), dried overnight at 37∘C,
dehydrated in an alcohol series, cleared in Xylol, and enclosed
in Entellan.
2.4. �uanti�cation. All quanti�cations were performed
independently by two investigators who were blind to the
experimental groups. e mean scores of the two investiga-
tors were used in all statistical analyses.
2.4.1. Synaptophysin. To determine the number of syn-
aptophysin-immunoreactive presynaptic boutons (SIPBs),
appropriate sections were digitised and photomicrographed
using a Zeiss Axioskop microscope, equipped with a 100x oil
immersion objective and a 10x projection lens. e selection
of areas to be quanti�ed was performed with the use of Stereo
Investigator (Microbright�eld soware, Williston, VT, �SA).
is soware was only used to draw regions of interest and
to take pictures. SIPBs were analysed in the prelimbic area
(PRL), the cingulate gyrus (GC) and in the CA1, CA3 and
dentate gyrus (DG) of the hippocampus (1.6mm and 0.9mm
anterior and 2.1mm posterior to bregma, respectively).
Within the PRL andGC, two square boxes were placed within
the borders of the intended brain areas. In the hippocampus,
two randomly chosen regions per section were analysed in
the stratum radiatum of area CA1 (SR), stratum lucidum
of area CA3 (SL), inner molecular layer (IML), and outer
molecular layer (OML) of the DG (Figure 1). Brain regions
were based on the mouse brain atlas of Franklin and Paxinos
[35]. We have not distinguished between le and right brain
regions. In total, four pictures were taken from each brain
region (two investigators, two pictures each per brain region).
All images taken were then processed with ImageJ (National
Institutes of �ealth) for automatic quanti�cation of the
SIPBs. Images were �rst converted to 8-bit gray scale and
then to 16-bit; �nally, contrast was enhanced. e threshold
was set at 26471–33153 for the males and at 27242–30840 for
the females. e thresholds were inevitably diﬀerent due to
diﬀerences in the staining sessions. Particles ranging between
0.1 and 4.5 𝜇𝜇m2 (circularity 0.0-1.0) were considered to be
normal-sized SIPBs and included in the analysis.Mean scores
per brain area were normalised (WT set as 100%), and these
normalised scores were used in the analyses.
2.4.2. Doublecortin. Appropriate sections were digitised and
quanti�ed using a Zeiss Axioskop microscope equipped
with the Microbright�eld soware (Williston, VT, �SA).
Quantitative analyses were performed with a computer-
assisted analysis system (Stereo Investigator). For every
mouse, doublecortin-positive cells (Figure 2) were counted
in the entire hippocampus in 3 diﬀerent sections (at 2.1mm,
2.4mm, and 2.7mm posterior to bregma). e brain regions
were based on the mouse brain atlas of Franklin and Paxinos
[35]. We have not distinguished between le and right brain
regions. e contours of the hippocampi were drawn at 5x
magni�cation, and cells were counted at 20x magni�cation.
e mean number of doublecortin-positive newly formed
neurons was used in the analysis.
IML
OML
SL
SR
F 1: Placement of contours for the analysis of the number
of synaptophysin-immunoreactive presynaptic boutons in the hip-
pocampus. e squares indicate the randomly chosen areas in the
inner (IML) and outer molecular layer (OML) of the dentate gyrus,
the stratum lucidum (SL) of the CA3, and the stratum radiatum (SR)
of the CA1.
F 2: Representative doublecortin-immunostained neurons in
the dentate gyrus of the hippocampus (coronal section).
2.5. Statistical Analysis. All statistical analyses were per-
formed with SPSS 16.0. Data were separately analysed for
male and female mice with univariate ANOVAs with geno-
type as the independent factor, followed by Tukey’s post hoc
�SD. e statistical signi�cance was set at 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
3. Results
3.1. Decreased Amount of SIPBs in Female ApoE4 Mice. In
female mice, an eﬀect of genotype was found on the num-
ber of synaptophysin-immunoreactive presynaptic boutons
(SIPBs) in the inner molecular layer (IML) of the dentate
gyrus in the hippocampus (𝐹𝐹 𝐹 𝐹𝑃𝐹𝐹𝐹, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). Post
hoc analysis revealed a signi�cant decrease in the number
of SIPBs in female apoE4 mice compared with female wild-
type (WT) mice (WT: 𝑀𝑀 𝐹 𝑃𝑃𝑃, SEM 𝐹 𝐹𝑃𝐹7; apoE4:
𝑀𝑀 𝐹 7𝑀.28, SEM 𝐹 2𝑃𝑀𝑃; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, Figure 3). ere were no
signi�cant diﬀerences in the number of SIPBs in the cortex
(prelimbic area and cingulate gyrus) or in other regions of
the hippocampus (outer molecular layer, stratum radiatum,
and stratum lucidum). Inmalemice, therewere no signi�cant
diﬀerences between the genotypes in the number of SIPBs in
any of the investigated brain regions.
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F 3: Number of synaptophysin-immunoreactive presynaptic boutons (SIPBs) in the prelimbic area (PRL), the cingulate gyrus (GC),
and the stratum radiatum (SR), stratum lucidum (SL) and the inner (IML) and outer molecular layer (OML) of the dentate gyrus in the
hippocampus. In female mice, there was a signi�cant e�ect of genotype on the number of SIPBs in the IML (𝑛𝑛 𝑛 𝑛/group, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃).
ApoE4 female mice have less SIPBs than female wild-type mice (∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). In other brain regions, no signi�cant di�erences were found
(𝑛𝑛 𝑛 𝑛/group, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). In male mice, there were no signi�cant e�ects found in any of the brain regions (𝑛𝑛 = 6–8/group, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). Error
bars show mean ± SEM.
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F 4: Neurogenesis in the dentate gyrus of the hippocam-
pus. In female mice, a trend was observed in the number of
doublecortin-positive newly formed neurons between genotypes (𝑛𝑛
= 6–7 mice/group, #𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃). e data strongly indicate that
neurogenesis is increased in female apoE knockout mice compared
with female wild-typemice. Inmales, no diﬀerences in neurogenesis
were found (𝑛𝑛 = 5–7 mice/group, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). Error bars show mean
± SEM.
3.2. Increased Neurogenesis in Female ApoE ko Mice. A trend
was observed in the number of doublecortin-positive newly
formed neurons between genotypes in female mice (𝐹𝐹 𝑃
3𝑃𝑃31,𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃, Figure 4).ere was a strong indication that
neurogenesis is increased in female apoE ko mice compared
with femaleWTmice. Inmalemice, there were no signi�cant
diﬀerences in neurogenesis between the genotypes.
4. Discussion
In this study, we investigated sex diﬀerences in apoE, focusing
on presynaptic density and neurogenesis, parameters related
to cognitive functioning. We studied these parameters in
diﬀerent apoE models of Alzheimer’s disease (AD) and
vascular disease in both male and female mice. We found a
decreased presynaptic density in middle-aged female apoE4
mice and a trend towards increased neurogenesis in middle-
aged female apoE knockout (apoE ko) mice compared with
wild-type (WT) mice. In male mice, no diﬀerences between
genotypes could be detected.
In female apoE4 mice, we found a decrease in the num-
ber of synaptophysin-immunoreactive presynaptic boutons
(SIPBs) in the inner molecular layer (IML) of the dentate
gyrus compared with controls. To our knowledge, no other
studies have investigated presynaptic density in aging female
apoE4 or apoE ko mice. Studies in male mice either showed
no diﬀerence between apoE4, apoE ko, and WT mice or
demonstrated a decrease in presynaptic density in aged apoE
ko mice [36, 37]. e decrease in SIPBs in our female apoE4
mice is in line with autopsy studies in which a decrease in
synaptic proteins or synaptic density was found in male and
female patients with mild cognitive impairment (MCI) or
AD compared with controls [38–40]. However, Scheﬀ et al.
[38, 39] did not �nd a relationship of this decresase with the
APOE genotype (𝜀𝜀2, 𝜀𝜀3, 𝜀𝜀4).
e fact that we only found an eﬀect in the molecular
layer of the dentate gyrus and not in other regions of the
hippocampus or in the cortex could indicate that mice at this
age are at an early stage of the disease. e molecular layer of
the dentate gyrus of the hippocampus receives a direct input
from the entorhinal cortex via the perforant pathway [41, 42].
Degeneration of these areas is an early event in both AD
and cardiovascular disease [39, 43, 44]. Others have found
that the connections between the entorhinal cortex and the
molecular layer of the dentate gyrus are selectively vulnerable
to synaptic loss [45] in aging humans [39, 46] as well as in
several animal models of aging [47, 48]. Neurodegeneration
spreads from the entorhinal cortex to the molecular layer
of the dentate gyrus and from there to the CA1 and CA3
regions of the hippocampus. Finally, the cerebral cortex,
like the prefrontal cortex, is aﬀected when the spreading of
neurodegeneration continues. As we only found an eﬀect in
the molecular layer of the dentate gyrus and not in the CA1
and CA3 regions or in other cortex regions in our current
study, we assume that these middle-aged mice are at an early
stage of the disease.
In our female mice, we found the trend of an increased
number of doublecortin-positive newly formed neurons,
indicating that neurogenesis is enhanced in female apoE ko
mice compared with controls. is result contrasts with that
of Li et al. [49], who found a decrease in neurogenesis in
female apoE ko mice. However, their mice were aged 6-7
months, which is much younger than our 12 to 15-month-
old mice. It is possible that at an older age a compensatory
mechanism, with an increased number of synapses and/or
neurogenesis, is established in response to synaptic failure
[50] or insults to the brain [51, 52].
In contrast to the female mice, we did not �nd any
diﬀerences in presynaptic density or in neurogenesis between
male apoE4, apoE ko, andWTmice. e absence of an eﬀect
of genotype on the number of SIPBs in male mice is in
line with Levi et al. [36], who did not observe diﬀerences
in presynaptic density in the hippocampus of male apoE3,
apoE4, apoE ko, or WT mice. Furthermore, Liraz et al. [53]
were not able to detect diﬀerences between male apoE3 and
apoE4 in hippocampal synaptophysin levels, as determined
by western blot. However, Veinbergs et al. [37] did �nd
a decrease in presynaptic density in the hippocampus and
frontoparietal cortex of aged male apoE ko mice. In human
autopsy studies, male and female patients with AD or MCI
are oen found to have synaptic loss compared with controls
[38–40]. It should be noted however, that the pattern of
relative diﬀerences between the genotypes for the number of
SIPBs is similar for males and females in this study, when
looking at the inner and outer molecular layer of the dentate
gyrus. Nevertheless, only the decrease in the number of SIPBs
in the IML in female apoE4mice comparedwithWT controls
reaches statistical signi�cance.
Both in AD patients and in AD and apoE mouse models,
con�icting results have been found regarding neurogenesis
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in male sex. Most studies on AD showed a decrease in
neurogenesis in both humans [54] and inAPP andPS1mouse
models [55, 56]. Con�icting studies found an increase in
neurogenesis inmale AD patients [52] and in PDGF-APP Sw ,
Ind AD transgenic mice [57]. However, the �rst study suﬀers
from methodological issues concerning diﬀerences between
the AD and control group in age, sex, and postmortem inter-
val. In studies of the apoEmousemodel, only one reported on
male mice. is study by Levi and Michaelson [51] reported
that neurogenesis, as measured immunohistochemically by
doublecortin staining, is increased in 6-month-oldmale apoE
ko mice and even more in apoE4 mice. In contrast, we did
not �nd any diﬀerences in neurogenesis in our male mice.
is discrepancy could possibly result from the age diﬀerence
(6 versus 11 months) between the mice in these studies.
It should be noted, however, that visual inspection of the
neurogenesis data gives a similar impression for both male
and female mice. We cannot exclude the possibility that we
would have seen the same trend in male mice with a larger
group of animals.
e present �ndings support the previously found sex
diﬀerences between APOE genotypes. It is possible that
estrogen plays a role, as it has many eﬀects on the vasculature
and on the brain. While estrogen’s eﬀects on the vasculature
are mainly positive [7, 58–60], its interaction with apoE4 in
the brain can have detrimental eﬀects. In vitro regulation
of APOE by estrogen is allele-dependent [61], and estradiol
does not facilitate neurite outgrowth in the presence of apoE4,
while it does so in the presence of apoE2 and apoE3 [33].
Hormone replacement therapy is not bene�cial to cognitive
function in women who carry at least one 𝜀𝜀4 allele [31,
32]; however, it can lower the incidence of AD and reduce
cognitive decline in women not carrying the 𝜀𝜀4 allele [62, 63].
In addition, female carriers of an 𝜀𝜀4 allele, with an increased
reproductive period and therefore a longer lifetime exposure
to estrogen, have an increased risk for dementia and AD
[64]. e harmful eﬀect of estrogen in those carrying the
APOE4 genotype could also explain the stronger association
of APOE4 with AD in women [26–28] and the increased
susceptibility of female apoE4mice to spatialmemory de�cits
[29, 30]. In contrast, androgens have been shown to protect
against apoE4-induced cognitive de�cits [65]. Androgen-
treated female apoE4 mice improved their performance in
a spatial memory test. However, male apoE4 mice, which
initially did not show any de�cits, were impaired in spatial
memory aer blockade of androgen receptors. e current
result, where only female apoE4 mice show a decreased
number of SIPBs, is also consistent with this view of a speci�c
female susceptibility to the negative eﬀect of apoE4.
In our apoE mouse models, several mechanisms are
involved in producing both the decrease in presynaptic bou-
tons in female apoE4mice and the increase in neurogenesis in
female apoE ko mice. e severely compromised vasculature
in apoE ko mice (severe atherosclerosis, impaired vascular
endothelium-dependent relaxation, and aortic stiﬀening [66–
68]) results in a compensatory eﬀect by increased neuroge-
nesis. e speci�c interaction of apoE4 with estrogen, even
though their vasculature is less aﬀected than that of apoE ko
mice (hypercholesterolemia and accelerated atherosclerosis
[17]), results in a deleterious eﬀect in the form of a loss of
synapses. In addition,male apoE4mice could possibly bene�t
from protection by androgens from the eﬀects of apoE4. e
fact that a compensatory mechanism can be observed in
female apoE komice, in contrast tomale apoE komice, could
be due to their diﬀerence in estrogen exposure. However,
we should interpret the trend of increased neurogenesis in
femalemicewith caution. Although there is no indication of a
trend in the male data, visual inspection of the graphs of the
neurogenesis data gives a similar impression for both male
and female mice. Further research is warranted to clarify this
matter.
We found a diﬀerence in females compared with males
in the number of presynaptic boutons and amount of neu-
rogenesis. Although the slightly higher age of the female
group should be kept in mind, we do not expect a large
in�uence due to an age diﬀerence of only two months.
Because our female mice can be considered premenopausal,
large hormonal �uctuations are absent. erefore, both our
male and female mice belong to the same stable age range.
e C57BL6/J wild-type mice we use in the current
study were obtained from Harlan Laboratories, Inc. (Horst,
e Netherlands). It is known that these mice carry a gene
mutation resulting in an alpha-synuclein gene deletion [69].
Because we obtained the apoE4 and apoE ko mice from
diﬀerent vendors, this could have in�uenced our results.
e alpha-synuclein deletion has some eﬀects on synapse
function related to neurotransmitter mobilisation [70–72].
However, basal synaptic transmission is unimpaired [70], and
there are no indications of an altered number of (pre)synapses
or neurogenesis in C57BL6/alpha-synuclein deletion mice
from Harlan. us, although we should keep this limitation
in mind when interpreting our results, the use of these WT
mice is not expected to signi�cantly alter the outcomes of the
experiments.
In the present study, we used the presynaptic marker
synaptophysin to obtain information on presynaptic density
in apoE4 and apoE ko mice. Measuring SIPBs is only one
indicator of the number of synapses. Future studies using
postsynaptic markers, such as PSD 95, or electron micro-
scopic evaluation of the number of synapses are needed to
acquire a more complete picture of synaptic density in these
mouse models.
5. Conclusion
To our knowledge, this is the �rst investigation of presynaptic
density in aging female apoE4 and apoE ko mice. We found
a decrease in presynaptic density in the hippocampus of
middle-aged female apoE4 mice compared with WT mice.
is may be the result of a speci�c harmful interaction of
estrogen with apoE4, as we did not observe any diﬀerences
in male mice. In addition, we found neurogenesis to be
increased in middle-aged female apoE ko mice. Previous
studies have suggested a compensatory mechanism for
synaptic failure by temporarily increasing the number of
synaptic contacts and/or neurogenesis.e trend of increased
neurogenesis found in female apoE ko mice in our study
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supports this hypothesis. Our results support the previously
determined sex-speci�c diﬀerences observed between APOE
genotypes, which could account for some of the sex diﬀer-
ences in AD and CVD. Sex diﬀerences should be taken into
account in any research concerning CVD, AD, or apoE.
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